Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa
NCT04856930 is registered in ClinicalTrials.gov with Vanda Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa
- Lead sponsor
- Vanda Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 7, 2021
- Completion date
- December 14, 2022
- Enrollment
- 149 (actual)
- Sites
- 34
Conditions
As the registry lists them; a condition with its own page is linked.